We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
Read MoreHide Full Article
Teva Pharmaceutical Industries Limited (TEVA - Free Report) announced positive results from two phase II/III studies on its new migraine drug Ajovy in patients with chronic and episodic migraines in Japan.
The company has an exclusive license agreement with Otsuka for the development and sales of Ajovy in Japan. The medicine is being developed by Otsuka in the country.
Preliminary data from the studies showed that the primary endpoints were achieved with both clinical and statistical significance compared to placebo. The studies also met all the secondary endpoints by demonstrating statistically significant improvements compared to placebo.
Detailed results from the study will be presented at the upcoming medical conference.
Otsuka/Teva will file regulatory applications seeking approval of Ajovy in Japan based on data from these studies.
Shares of Teva were up 7.2% following the above favorable news on Monday. However, the stock has declined 44.1% in the past year compared with the industry’s decrease of 6.2%.
Ajovy for the prevention of chronic/episodic migraine was approved by the FDA in September 2018 and in the EU in April 2019. The drug is the first and the only anti-CGRP medicine offering both quarterly and monthly dosing options. In the first nine months of 2019, Ajovy recorded sales of $68 million.
Last week, the FDA approved an autoinjector device for Ajovy injection, which is expected to be available to patients in the coming months. During the third-quarter conference call held last November, management informed that Ajovy saw a decline in new prescription shares, which was due to patients’ preference for auto injectors while Ajovy is available as a subcutaneous injection. The approval for the autoinjector device for Ajovy could reignite growth for the drug in 2020.
However, Ajovy faces intense competition from Amgen (AMGN - Free Report) / Novartis (NVS - Free Report) and Lilly’s (LLY - Free Report) respective CGRPs of Aimovig and Emgality. Both were approved by the FDA in mid-2018. Both are also approved in the EU.
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
Teva Pharmaceutical Industries Limited (TEVA - Free Report) announced positive results from two phase II/III studies on its new migraine drug Ajovy in patients with chronic and episodic migraines in Japan.
The company has an exclusive license agreement with Otsuka for the development and sales of Ajovy in Japan. The medicine is being developed by Otsuka in the country.
Preliminary data from the studies showed that the primary endpoints were achieved with both clinical and statistical significance compared to placebo. The studies also met all the secondary endpoints by demonstrating statistically significant improvements compared to placebo.
Detailed results from the study will be presented at the upcoming medical conference.
Otsuka/Teva will file regulatory applications seeking approval of Ajovy in Japan based on data from these studies.
Shares of Teva were up 7.2% following the above favorable news on Monday. However, the stock has declined 44.1% in the past year compared with the industry’s decrease of 6.2%.
Ajovy for the prevention of chronic/episodic migraine was approved by the FDA in September 2018 and in the EU in April 2019. The drug is the first and the only anti-CGRP medicine offering both quarterly and monthly dosing options. In the first nine months of 2019, Ajovy recorded sales of $68 million.
Last week, the FDA approved an autoinjector device for Ajovy injection, which is expected to be available to patients in the coming months. During the third-quarter conference call held last November, management informed that Ajovy saw a decline in new prescription shares, which was due to patients’ preference for auto injectors while Ajovy is available as a subcutaneous injection. The approval for the autoinjector device for Ajovy could reignite growth for the drug in 2020.
However, Ajovy faces intense competition from Amgen (AMGN - Free Report) / Novartis (NVS - Free Report) and Lilly’s (LLY - Free Report) respective CGRPs of Aimovig and Emgality. Both were approved by the FDA in mid-2018. Both are also approved in the EU.
Zacks Rank
Teva currently carries a zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>